Novartis' (NOVN SW/NVS) Ianalumab receives FDA breakthrough therapy designation for Sjögren’s disease and plans global submission in early 2026

Novartis' (NOVN SW/NVS) Ianalumab receives FDA breakthrough therapy designation for Sjögren’s disease and plans global submission in early 2026.

Novartis has received FDA breakthrough therapy designation for Ianalumab to treat Sjögren’s disease, which indicates a significant validation of its potential and may accelerate its path to market. The plan for a global submission by early 2026 suggests confidence in regulatory support, potentially enhancing Novartis's competitive position in the pharmaceuticals sector. This development could positively affect investor sentiment and expectations regarding pipeline growth and future revenues.